Abstract 32P
Background
Worldwide breast cancer morbidity and mortality was still positioned in the top. Epidemiological data for breast cancer in Bali was not available although is essential for planning health measures. This study aimed to summarise the demographics of breast cancer subjects in Sanglah Genral Hospital from 2012-2019 and emphasize variables that related.
Methods
This is a descriptive study, collecting all breast cancer subjects data from January 2012 to 2019. All data from the cancer registry were analyzed and tabulated. Data were described as count and percentages. Reasoning analysis was done by looking at the counts from year to year. Information for counting age standardized rate was taken in national census data of population in Bali. Literature review if articles were also screened for the filtering out of the data regarding epidemiology of breast cancer in worldwide for comparison.
Results
A total of 1627 cases from 2012 to 2019 were included in this study for analysis. The incidence of breast cancer increase from 187 cases to 364 cases from 2013 to 2016. The age-standardized incidence rate was 84.33 per 100.000 women Balinese population. Most cases were found in advanced stages, stage IIIB (29.38%) and stage IV (22.56%). The most common tumor status found was T4 (49.78%), N1 (41.49%), and 22.5% were found to have metastasis. Lung metastasis dominated all the metastasis cases with the rate of 42.35%. Majority of histopathology subtypes in breast cancer subjects were invasive carcinoma of non special type (NST) (78.8%), followed by invasive lobular carcinoma (12.4%). From 1627 subjects, only 1160 (71.3%) had subtype tested, with luminal B subtype dominated the cases (36.5%).
Conclusions
Geographical and phenotypical variations differ from breast cancer subject epidemiology. Thus, statistical data should be done in each region for a better diagnosis and treatment care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract
133P - Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract